GLP-1 Clinical Trial Results Explained: STEP, SURMOUNT, and SELECT in Plain Language

GLP-1 medications didn't become the most talked-about weight-loss drugs in decades on hype alone. They got there through some of the largest, most rigorously designed clinical trials in obesity medicine history. But reading trial summaries written for physicians is like reading a legal contract for entertainment — technically possible, mostly miserable.

This guide translates the key trial data into language that actually helps you understand what these medications can and can't do.

The STEP Trials — Semaglutide for Weight Management

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the clinical foundation for semaglutide's use in weight management. Four major trials, thousands of participants, published in the New England Journal of Medicine.

STEP 1 — The Headline Trial

1,961 adults with obesity (BMI ≥30) or overweight with comorbidities received either 2.4mg semaglutide weekly or placebo, plus lifestyle intervention, for 68 weeks.

• Semaglutide group lost an average of 14.9% of body weight vs. 2.4% for placebo.
• 86.4% of semaglutide patients lost ≥5% body weight (vs. 31.5% placebo).
• Over one-third lost ≥20% of body weight.

To put that in real terms: a 250-pound participant averaged a 37-pound loss over about 16 months.

STEP 2 — Patients with Type 2 Diabetes

In patients managing both obesity and diabetes, semaglutide produced 9.6% weight loss (vs. 3.4% placebo). Weight loss was lower than STEP 1, consistent with the observation that diabetes medications' weight effects are often blunted in patients with insulin resistance.

STEP 3 & 4 — Intensive Lifestyle and Continuation

STEP 3 combined semaglutide with intensive behavioral therapy, achieving 16% weight loss. STEP 4 demonstrated that stopping semaglutide after 20 weeks led to significant weight regain — reinforcing that GLP-1 therapy manages obesity rather than curing it.

SURMOUNT Trials — Tirzepatide for Obesity

Tirzepatide (the active ingredient in Mounjaro and Zepbound) acts on both GLP-1 and GIP receptors. The SURMOUNT trials evaluated its weight-loss efficacy.

SURMOUNT-1 — The Record-Setting Trial

2,539 adults without diabetes received tirzepatide at 5mg, 10mg, or 15mg weekly for 72 weeks.

• 15mg group: 22.5% average weight loss (vs. 2.4% placebo).
• 10mg group: 21.4% average weight loss.
• 5mg group: 15.0% average weight loss.
• Over half of patients on 15mg lost ≥20% body weight — results previously only achievable with bariatric surgery.

The SELECT Trial — Cardiovascular Outcomes

Perhaps the most clinically significant trial for GLP-1 medications, SELECT studied semaglutide 2.4mg in 17,604 adults with established cardiovascular disease and BMI ≥27 — but without diabetes.

• 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death).
• Benefits appeared independent of the amount of weight lost.
• This trial changed the conversation from "weight-loss drug" to "cardiometabolic medication."

What the Trials Don't Tell You

Clinical trials are designed to measure average effects under controlled conditions. Some important caveats:

• Trial participants received lifestyle counseling. The drug alone wasn't responsible for all the weight loss — diet and exercise contributed.
• Adherence in trials is higher than real life. Participants are monitored, motivated, and medication-compliant at rates typical patients may not match.
• Individual variation is enormous. Some patients lose 25%+ of body weight; others lose less than 5%. The averages mask wide distributions.
• Long-term data (5+ years) is limited. Most pivotal trials ran 68–72 weeks. We're still learning about decade-long outcomes.